French Clinical Datbase of Melanoma Patients (RIC-Mel)

NCT03315468 | Recruiting

• 1 other identifier: Prog 09/37-11
• Study Type: observational
• Target: 16,000
• Locations: 1 country
• Sites: 1

Brief Summary

With a high incidence, low survival rates and limiter availability of effective treatment, melanoma is one of the research priorities for health authorities. Optimizing the development of both academic and private research requires the availability information on the features of patients. To meet this need, the French Multidisciplinary Melanoma Group (GMFMel) in collaboration with INCa (French National Cancer Institute), the CeNGEPS (National Centre for Healthcare Products Trial Management) and the CIC-BT0503 from Nantes University Hospital (Biotherapy Clinical Centre of Investigation) has set up in April 2011 a Clinical Investigation Network for melanoma, called the CeNGEPS-GMFMel network. Nowadays, the network is named : RIC-Mel : network for Research and Clinical Investigation on Melanoma. Aims of the network are to promote translational and epidemiological projects as well as to optimize the achievements of clinical trials. To achieve these goals, a database was launched in 2012 that gives a permanently updates mapping of melanoma treated in France with the key information needed for any research projects.

Conditions

Melanoma (Skin)

Keywords

melanoma; database; cohort

Outcome Measures

Primary Outcomes (1)

• Overall survival of melanoma patients included in the RIC-Mel database

  Overall survival if defined as the time between the primary melanoma tumour removal and the death or the date of data extraction from the RIC-Mel database for alive patients.

  5 years

Secondary Outcomes (8)

• Percentage of melanoma patients included in the RIC-Mel database categorized by genders

  through study completion, an average of 5 years

• Percentage of melanoma patients included in the RIC-Mel database categorized by histological subtypes

  Day 1

• Percentage of melanoma patients included in the RIC-Mel database categorized by breslow thickness

  day 1

• Percentage of melanoma patients included in the RIC-Mel database categorized by ulceration

  day 1

• Percentage of melanoma patients included in the RIC-Mel database categorized by Melanoma stage

  day 1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with melanoma

You may qualify if:

• Patient with melanoma, of any stage,
• Patient agreed to participate.

You may not qualify if:

• Individuals under court protection

Sponsors & Collaborators

• Nantes University Hospital: lead
• CENGEPS: collaborator
• Bristol-Myers Squibb: collaborator
• Hoffmann-La Roche: collaborator
• GlaxoSmithKline: collaborator
• Amgen: collaborator

Study Sites (1)

Nantes University Hospital

Nantes, 44093, France

RECRUITING

MeSH Terms

Conditions

Melanoma

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Gaëlle Quereux, PU-PH

  Nantes University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Gaëlle Quereux, PU-PH

CONTACT

gaelle.quereux@chu-nantes.fr

Amir Khammari

CONTACT

amir.khammari@chu-nantes.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 6, 2017
• First Posted: October 20, 2017
• Study Start: March 1, 2012
• Primary Completion (Estimated): March 1, 2030
• Study Completion (Estimated): March 1, 2030
• Last Updated: July 22, 2025

Record last verified: 2025-07

Locations

FR (1)